Thermo Fisher Scientific Releases 2023 Corporate Social Responsibility Report

Report highlights company's commitments to all of its stakeholders and society

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its 2023 Corporate Social Responsibility (CSR) report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

�Thermo Fisher is driven by a profound Mission to enable our customers to make the world healthier, cleaner, and safer," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "We also understand our obligation goes beyond enabling our customers' success and extends to making the world a better place by supporting our communities, being a good steward of our planet and creating a great work environment for our colleagues. I am proud of what we've accomplished so far and deeply grateful to our global team for their passion for fulfilling our Mission and delivering on our commitments to society."

Highlights of the report include:

Communities

  • Collectively volunteered more than 100,000 hours to support communities around the world.
  • Reached more than 60,000 students through the Thermo Fisher Scientific Junior Innovators Challenge in partnership with the Society for Science, the premier STEM competition for middle schoolers in the U.S.
  • Established collaborations with the National Quality Minority Forum, to increase diversity in clinical trials, and Project HOPE, to advance health equity among HIV-positive youth in sub-Saharan Africa.

Environment

  • Achieved key milestones toward the company's goal of net-zero emissions by 2050, including the sourcing 41% of global electricity from renewable energy.
  • Announced a new agreement to power over half of Thermo Fisher's European footprint with 100% renewable energy by 2025.
  • Established new commitment to achieve 80% renewable electricity utilization globally by 2030.

Colleagues

  • Advanced our vibrant and inclusive culture where colleagues' unique backgrounds and perspectives are embraced.
  • Continued to develop the workforce, including launching new training programs for emerging technologies and an internal generative AI platform.
  • Enhanced global access to wellness resources.

In reporting its CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks, including the Global Reporting Initiative (GRI) Standards, the IFRS Foundation's SASB Standards, the Task Force on Climate-related Financial Disclosures (TCFD) and the United Nations Sustainable Development Goals (SDGs). Thermo Fisher makes additional topic-specific ESG data available to key stakeholders through its annual CDP report and voluntary disclosure of EEO-1 information.

Learn more at www.thermofisher.com/CSR .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

Media:
Sandy Pound
Thermo Fisher Scientific
781-622-1223
sandy.pound@thermofisher.com

Investors:
Rafael Tejada
Thermo Fisher Scientific
781-622-1356
rafael.tejada@thermofisher.com

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 706921. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials". A replay of the call will be available under "News, Events & Presentations" through Friday, February 14, 2025.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×